Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
First-in-human use of a modular capsid virus-like vaccine platform: an open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2.
Smit MJ, Sander AF, Ariaans MBPA, Fougeroux C, Heinzel C, Fendel R, Esen M, Kremsner PG, Ter Heine R, Wertheim HF, Idorn M, Paludan SR, Underwood AP, Binderup A, Ramirez S, Bukh J, Soegaard M, Erdogan SM, Gustavsson T, Clemmensen S, Theander TG, Salanti A, Hamborg M, de Jongh WA, McCall MBB, Nielsen MA, Mordmüller BG; COUGH-1 trial study group. Smit MJ, et al. Among authors: underwood ap. Lancet Microbe. 2023 Mar;4(3):e140-e148. doi: 10.1016/S2666-5247(22)00337-8. Epub 2023 Jan 18. Lancet Microbe. 2023. PMID: 36681093 Free PMC article. Clinical Trial.
Overcoming Culture Restriction for SARS-CoV-2 in Human Cells Facilitates the Screening of Compounds Inhibiting Viral Replication.
Ramirez S, Fernandez-Antunez C, Galli A, Underwood A, Pham LV, Ryberg LA, Feng S, Pedersen MS, Mikkelsen LS, Belouzard S, Dubuisson J, Sølund C, Weis N, Gottwein JM, Fahnøe U, Bukh J. Ramirez S, et al. Antimicrob Agents Chemother. 2021 Jun 17;65(7):e0009721. doi: 10.1128/AAC.00097-21. Epub 2021 Jun 17. Antimicrob Agents Chemother. 2021. PMID: 33903110 Free PMC article.
Neutralisation titres against SARS-CoV-2 are sustained 6 months after onset of symptoms in individuals with mild COVID-19.
Underwood AP, Sølund C, Fernandez-Antunez C, Villadsen SL, Winckelmann AA, Bollerup S, Mikkelsen LS, Sørensen AL, Feng S, Fahnøe U, Lassauniere R, Fomsgaard A, Ramirez S, Weis N, Bukh J. Underwood AP, et al. EBioMedicine. 2021 Sep;71:103519. doi: 10.1016/j.ebiom.2021.103519. Epub 2021 Aug 19. EBioMedicine. 2021. PMID: 34419923 Free PMC article.
Analysis of Neutralization Titers against SARS-CoV-2 in Health-Care Workers Vaccinated with Prime-Boost mRNA-mRNA or Vector-mRNA COVID-19 Vaccines.
Sølund C, Underwood AP, Fernandez-Antunez C, Bollerup S, Mikkelsen LS, Villadsen SL, Fahnøe U, Winckelmann AA, Feng S, Nørløv Vinten CA, Dalegaard MI, Vizgirda G, Sørensen AL, Ramirez S, Bukh J, Weis N. Sølund C, et al. Among authors: underwood ap. Vaccines (Basel). 2022 Jan 4;10(1):75. doi: 10.3390/vaccines10010075. Vaccines (Basel). 2022. PMID: 35062736 Free PMC article.
Durability and breadth of neutralisation following multiple antigen exposures to SARS-CoV-2 infection and/or COVID-19 vaccination.
Underwood AP, Sølund C, Fernandez-Antunez C, Villadsen SL, Mikkelsen LS, Fahnøe U, Bollerup S, Winckelmann AA, Schneider UV, Binderup A, Vizgirda G, Sørensen AL, Vinten CN, Dalegaard MI, Ramirez S, Weis N, Bukh J. Underwood AP, et al. EBioMedicine. 2023 Mar;89:104475. doi: 10.1016/j.ebiom.2023.104475. Epub 2023 Mar 2. EBioMedicine. 2023. PMID: 36870117 Free PMC article.
Neutralizing antibody and CD8+ T cell responses following BA.4/5 bivalent COVID-19 booster vaccination in adults with and without prior exposure to SARS-CoV-2.
Underwood AP, Sølund C, Jacobsen K, Binderup A, Fernandez-Antunez C, Mikkelsen LS, Inekci D, Villadsen SL, Castruita JAS, Pinholt M, Fahnøe U, Ramirez S, Brix L, Weis N, Bukh J. Underwood AP, et al. Front Immunol. 2024 Mar 20;15:1353353. doi: 10.3389/fimmu.2024.1353353. eCollection 2024. Front Immunol. 2024. PMID: 38571939 Free PMC article.
In vitro Characterization of Fitness and Convalescent Antibody Neutralization of SARS-CoV-2 Cluster 5 Variant Emerging in Mink at Danish Farms.
Lassaunière R, Fonager J, Rasmussen M, Frische A, Polacek C, Rasmussen TB, Lohse L, Belsham GJ, Underwood A, Winckelmann AA, Bollerup S, Bukh J, Weis N, Sækmose SG, Aagaard B, Alfaro-Núñez A, Mølbak K, Bøtner A, Fomsgaard A. Lassaunière R, et al. Front Microbiol. 2021 Jun 25;12:698944. doi: 10.3389/fmicb.2021.698944. eCollection 2021. Front Microbiol. 2021. PMID: 34248922 Free PMC article.
B cell characteristics define HCV reinfection outcome.
Underwood AP, Gupta M, Wu BR, Eltahla AA, Boo I, Wang JJ, Agapiou D, Abayasingam A, Reynaldi A, Keoshkerian E, Zhao Y, Brasher N, Walker MR, Bukh J, Maher L, Gordon T, Davenport MP, Luciani F, Drummer HE, Lloyd AR, Bull RA. Underwood AP, et al. J Hepatol. 2024 Apr 9:S0168-8278(24)00271-X. doi: 10.1016/j.jhep.2024.04.004. Online ahead of print. J Hepatol. 2024. PMID: 38604387 Free article.
Broadly neutralizing antibodies from an individual that naturally cleared multiple hepatitis C virus infections uncover molecular determinants for E2 targeting and vaccine design.
Keck ZY, Pierce BG, Lau P, Lu J, Wang Y, Underwood A, Bull RA, Prentoe J, Velázquez-Moctezuma R, Walker MR, Luciani F, Guest JD, Fauvelle C, Baumert TF, Bukh J, Lloyd AR, Foung SKH. Keck ZY, et al. PLoS Pathog. 2019 May 17;15(5):e1007772. doi: 10.1371/journal.ppat.1007772. eCollection 2019 May. PLoS Pathog. 2019. PMID: 31100098 Free PMC article.
50 results